We are monitoring the impact of COVID-19 on Latin America Ophthalmic Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5305
Share on
Share on

Latin America Ophthalmic Drugs Market Research Report - Segmented By Therapeutic Class, Product Type, Distribution Channel, Disease Indication, Dosage Form, Technology and Country (Brazil, Mexico, Argentina, Chile and Rest of Latin America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5305
Pages: 145

Latin America Ophthalmic Drugs Market Size (2021 to 2026)

As per the research report, the Latin American Ophthalmic Drugs market was valued at around USD 4.23 billion in 2021. It is expected to grow at a CAGR of 6.4% and be worth USD 5.77 billion by 2026. It captures 12% of the global market.

An increasing number of people suffering from glaucoma around the region and substantial innovation and funding in the development of combination treatments are driving the growth of the Latin American ophthalmic drugs market. In addition, other factors such as the FDA approvals, which raise medication approvals and increases surgeries in the ophthalmology industry due to the high prevalence of reactive defects, are fuelling the market growth.

The market is expanding as the population ages, the incidence of eye disorders increases, rise in healthcare spending, and an increase in the use of minimally invasive surgeries. In addition, the growing patient population in developed and developing countries and rising healthcare spending on eye illness are driving the ophthalmic drug market forward.

As the prevalence of eye problems develops, the demand for ophthalmic medications grows. Eye diseases have already emerged as potential threats to people’s visual experience in many industrialized and developing countries. As the prevalence of diabetes has increased in many areas, diabetes medicines have been introduced. Glaucoma has been on the public health agenda for millennia due to the difficulties in recognizing it early and the need for long-term treatment.

The long gestation period in new drugs and undesirable side effects impede the Latin American ophthalmic drugs market expansion. Furthermore, the market growth is limited by issues like well-known drugs falling off patent and big players being hampered by the time it takes for the new drugs to join the market. In addition, risks associated with ocular disorders and a lack of public understanding of ophthalmology are further estimated to hamper the market’s growth rate.

This research report on the Latin American ophthalmic drugs market has been segmented and sub-segmented into the following categories:

By Therapeutic Class: 

  • Anti-inflammatory Drugs
  • Anti-infective Drugs
  • Anti-glaucoma Drugs
  • Anti-allergy Drugs
  • Anti-VEGF Agents
  • Others

By Product Type: 

  • Prescription Drugs
  • Over-the-Counter Drugs 

By Distribution Channel: 

  • Hospital Pharmacies
  • Online Pharmacies
  • Independent Pharmacies
  • Drug Stores 

By Disease Indications: 

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders
  • Allergy
  • Uveitis
  • Others  

By Dosage Form: 

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms       

By Technology: 

  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small molecule
  • Others 

By Country: 

  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America

The ophthalmic drug market in Latin America is expected to increase steadily during the forecast period. The expanding usage of health insurance is projected to play an essential part in the regional market growth.  Latin America is projected to record a moderate share in the global ophthalmic drugs market in the coming years as the market growth is fueled by the rising number of patients from glaucoma and significant innovation and funding in the development of combination therapy. Also, the expanding prevalence of diabetes and rising healthcare spending are driving the Latin American ophthalmic drugs market. The major countries in the region, such as Brazil, Mexico, and Argentina, significantly contribute to regional market growth.

However, the Brazilian ophthalmic drugs market dominated the Latin American market in 2020, and it is likely to augment the significant growth over the forecast period. Brazil is investing a considerable amount of capital in healthcare. Although many non-diabetic individuals get cataracts, people with diabetes have a 60% higher probability of developing this eye condition at a younger age and a faster rate.

Furthermore, according to the World Health Organization (WHO), healthcare expenditure in Argentina accounted for a considerable portion of GDP, indicating that the Argentina government spent a significant amount of money on healthcare, boosting the expansion of the Latin American ophthalmic drugs market.

KEY MARKET PLAYERS:

A few prominent companies operating in the Latin American ophthalmic drugs market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.

1. Introduction           

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions                

2. Research Methodology                     

                2.1 Introduction         

                2.2 Research Phases

          2.2.1 Secondary Research           

          2.2.2 Primary Research 

          2.2.3 Econometric Modelling      

          2.2.4 Expert Validation  

                2.3 Analysis Design   

                2.4 Study Timeline    

3. Overview                 

                3.1 Executive Summary                

                3.2 Key Inferences   

                3.3 Epidemology        

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)              

                4.1 Market Drivers    

                4.2 Market Restraints                    

                4.3 Key Challenges   

                4.4 Current Opportunities in the Market        

5. Market Segmentation  

                5.1 Therapeutic Class                     

          5.1.1 Introduction           

          5.1.2 Anti-inflammatory Drugs  

    5.1.2.1 Nonsteroidal Anti-inflammatory Drugs

    5.1.2.2 Steroids

          5.1.3 Anti-infective Drugs            

    5.1.3.1 Anti-fungal Drugs

    5.1.3.2 Anti-bacterial Drugs

    5.1.3.3 Others

          5.1.4 Anti-glaucoma Drugs          

    5.1.4.1 Alpha Agonist

    5.1.4.2 Beta Blockers

    5.1.4.3 Prostaglandin Analogs

    5.1.4.4 Combined Medication

    5.1.4.5 Others

          5.1.5 Anti-allergy Drugs

          5.1.6 Anti-VEGF Agents

          5.1.7 Others      

          5.1.8 Y-o-Y Growth Analysis, By Therapeutic Class            

          5.1.9 Market Attractiveness Analysis, By Therapeutic Class          

          5.1.10 Market Share Analysis, By Therapeutic Class         

                5.2 Product Type       

          5.2.1 Introduction           

          5.2.2 Prescription Drugs               

          5.2.3 Over-the-Counter Drugs   

          5.2.4 Y-o-Y Growth Analysis, By Product Type    

          5.2.5 Market Attractiveness Analysis, By Product Type  

          5.2.6 Market Share Analysis, By Product Type    

                5.3 Distribution Channel         

          5.3.1 Introduction           

          5.3.2 Hospital Pharmacies            

          5.3.3 Online  Pharmacies              

          5.3.4 Independent Pharmacies & Drug Stores    

          5.3.5 Y-o-Y Growth Analysis, By Distribution Channel      

          5.3.6 Market Attractiveness Analysis, By Distribution Channel    

          5.3.7  Market Share Analysis, By Distribution Channel     

                5.4 Disease Indications                 

          5.4.1 Introduction           

          5.4.2 Dry Eye     

          5.4.3 Glaucoma

          5.4.4 Infection/Inflammation     

          5.4.5 Retinal Disorders  

    5.4.5.1 Wet Age-related Macular Degeneration

    5.4.5.2 Dry Age-related Macular Degeneration

    5.4.5.3 Diabetic Retinopathy

    5.4.5.4 Others

          5.4.6 Allergy      

          5.4.7 Uveitis      

          5.4.8 Others      

          5.4.9 Y-o-Y Growth Analysis, By Disease Indications         

          5.4.10 Market Attractiveness Analysis, By Disease Indications    

          5.4.11 Market Share Analysis, By Disease Indications      

                5.5 Dosage Form       

          5.5.1 Introduction           

          5.5.2 Liquid Ophthalmic Drug Forms        

          5.5.3 Solid Ophthalmic Drug Forms          

          5.5.4 Semisolid Ophthalmic Drug Forms

          5.5.5 Multicompartment Drug Delivery Systems               

          5.5.6 Other Ophthalmic Drug Forms        

          5.5.7 Y-o-Y Growth Analysis, By Dosage Form     

          5.5.8  Market Attractiveness Analysis, By Dosage Form  

          5.5.9  Market Share Analysis, By Dosage Form   

                5.6 Technology                 

          5.6.1 Introduction           

          5.6.2 Biologics   

          5.6.3 Cell Therapy           

          5.6.4 Gene Therapy       

          5.6.5 Drug Delivery         

          5.6.6 Small molecule      

          5.6.7 Others      

          5.6.8 Y-o-Y Growth Analysis, By Technology        

          5.6.9 Market Attractiveness Analysis, By Technology      

          5.6.10 Market Share Analysis, By Technology     

6. Geographical Analysis  

                6.1 Introduction         

          6.1.1 Regional Trends    

          6.1.2 Impact Analysis     

          6.1.3 Y-o-Y Growth Analysis        

    6.1.3.1 By Geographical Area

    6.1.3.2 By Therapeutic Class

    6.1.3.3 By Product Type

    6.1.3.4 By Distribution Channel

    6.1.3.5 By Disease Indication

    6.1.3.6 By Dosage Form

    6.1.3.7 By Technology

          6.1.4  Market Attractiveness Analysis     

    6.1.4.1 By Geographical Area

    6.1.4.2 By Therapeutic Class

    6.1.4.3 By Product Type

    6.1.4.4 By Distribution Channel

    6.1.4.5 By Disease Indication

    6.1.4.6 By Dosage Form

    6.1.4.7 By Technology

          6.1.5  Market Share Analysis      

    6.1.5.1 By Geographical Area

    6.1.5.2 By Therapeutic Class

    6.1.5.3 By Product Type

    6.1.5.4 By Distribution Channel

    6.1.5.5 By Disease Indication

    6.1.5.6 By Dosage Form

    6.1.5.7 By Technology

                6.2 Brazil       

                6.3 Mexico   

                6.4 Rest of Latin America       

7. Strategic Analysis                 

                7.1 PESTLE analysis   

          7.1.1 Political     

          7.1.2 Economic 

          7.1.3 Social         

          7.1.4 Technological         

          7.1.5 Legal          

          7.1.6 Environmental       

                7.2 Porter’s Five analysis        

          7.2.1 Bargaining Power of Suppliers        

          7.2.2 Bargaining Power of Consumers    

          7.2.3 Threat of New Entrants     

          7.2.4 Threat of Substitute Products and Services              

          7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                  

                8.1 Abbott Medical Optics, Inc.                 

          8.1.1 Overview 

          8.1.2 Product Analysis   

          8.1.3 Financial analysis  

          8.1.4 Recent Developments       

          8.1.5 SWOT analysis       

          8.1.6 Analyst View          

                8.2 Carl-Zeiss AG       

                8.3 Ellex Medical Lasers Ltd. 

                8.4 Essilor International S.A. 

                8.5 Hoya Corporation                    

                8.6 Insight Vision Inc.                     

                8.7 Nidek Co.Ltd        

                8.8 Novagali Pharma S A         

                8.9 Topcon Corporation          

                8.10 Ziemer Ophthalmic Systems AG.                    

9.Competitive Landscape

                9.1 Market share analysis      

                9.2 Merger and Acquisition Analysis 

                9.3 Agreements, collaborations and Joint Ventures   

                9.4 New Product Launches   

10.Market Outlook and Investment Opportunities                    

Appendix                     

                a) List of Tables                

                b) List of Figures        

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type and Packaged Containers along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Latin America Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  2. Latin America Dry Eye Market, By Region, From 2021 to 2026 (USD Billion)
  3. Latin America Glaucoma Market, By Region, From 2021 to 2026 (USD Billion)
  4. Latin America Infection/Inflammation Market, By Region, From 2021 to 2026 (USD Billion)
  5. Latin America Retinal Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  6. Latin America Allergy Market, By Region, From 2021 to 2026 (USD Billion)
  7. Latin America Uveitis Market, By Region, From 2021 to 2026 (USD Billion)
  8. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  9. Latin America Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  10. Latin America Anti-inflammatory Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  11. Latin America Anti-infective Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  12. Latin America Anti-glaucoma Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  13. Latin America Anti-allergy Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  14. Latin America Anti-VEGF Agents Market, By Region, From 2021 to 2026 (USD Billion)
  15. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  16. Latin America Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  17. Latin America Prescription Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  18. Latin America Over-the-Counter Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  19. Latin America Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  20. Latin America Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  21. Latin America Online Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  22. Latin America Independent Pharmacies & Drug Stores Market, By Region, From 2021 to 2026 (USD Billion)
  23. Latin America Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  24. Latin America Liquid Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  25. Latin America Solid Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  26. Latin America Semisolid Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  27. Latin America Multicompartment Drug Delivery Systems Market, By Region, From 2021 to 2026 (USD Billion)
  28. Latin America Other Ophthalmic Drug Forms Market, By Region, From 2021 to 2026 (USD Billion)
  29. Latin America Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)
  30. Latin America Biologics Market, By Region, From 2021 to 2026 (USD Billion)
  31. Latin America Cell Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  32. Latin America Gene Therapy Market, By Region, From 2021 to 2026 (USD Billion)
  33. Latin America Drug Delivery Market, By Region, From 2021 to 2026 (USD Billion)
  34. Latin America Small molecule Market, By Region, From 2021 to 2026 (USD Billion)
  35. Latin America Others Market, By Region, From 2021 to 2026 (USD Billion)
  36. Brazil Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  37. Brazil Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  38. Brazil Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  39. Brazil Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  40. Brazil Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  41. Brazil Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)
  42. Argentina Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  43. Argentina Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  44. Argentina Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  45. Argentina Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  46. Argentina Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  47. Argentina Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)
  48. Mexico Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  49. Mexico Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  50. Mexico Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  51. Mexico Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  52. Mexico Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  53. Mexico Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)
  54. Rest of Latin America Ophthalmic Drugs Market, By Disease Indication, From 2021 to 2026 (USD Billion)
  55. Rest of Latin America Ophthalmic Drugs Market, By Therapeutic Class, From 2021 to 2026 (USD Billion)
  56. Rest of Latin America Ophthalmic Drugs Market, By Product Type, From 2021 to 2026 (USD Billion)
  57. Rest of Latin America Ophthalmic Drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)
  58. Rest of Latin America Ophthalmic Drugs Market, By Dosage Form, From 2021 to 2026 (USD Billion)
  59. Rest of Latin America Ophthalmic Drugs Market, By Technology, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample